PRESS RELEASE published on 05/08/2024 at 08:30, 1 year 10 months ago Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024 Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024. The event will showcase new data on obefazimod's impact and mechanism of action Abivax Obefazimod Ulcerative Colitis Colon Cancer Digestive Disease Week 2024
BRIEF published on 05/07/2024 at 22:05, 1 year 10 months ago Abivax Announces Availability of Documents for Upcoming General Meeting Biotechnology Shareholder Information Corporate Governance Abivax General Meeting
BRIEF published on 05/07/2024 at 22:05, 1 year 10 months ago Abivax annonce la mise à disposition des documents pour la prochaine assemblée générale Biotechnologie Abivax Assemblée Générale Gouvernance D'Entreprise Informations Pour Les Actionnaires
PRESS RELEASE published on 05/07/2024 at 22:01, 1 year 10 months ago Abivax assemblée générale ordinaire annuelle et extraordinaire du 30 mai 2024 - Mise à disposition des documents préparatoires Abivax annonce la tenue de son assemblée générale annuelle et extraordinaire le 30 mai 2024 à Paris. Mise à disposition des documents préparatoires pour les actionnaires Biotechnologie Abivax Obefazimod Assemblée Générale Documents Préparatoires
PRESS RELEASE published on 05/07/2024 at 22:00, 1 year 10 months ago Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents Abivax informs shareholders of its ordinary and extraordinary general meeting on May 30, 2024, providing access to preparatory documents and details on participation. Obefazimod and Abivax information included Abivax Obefazimod General Meeting Clinical-stage Biotechnology Preparatory Documents
PRESS RELEASE published on 05/07/2024 at 22:00, 1 year 10 months ago Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents Abivax announces its annual ordinary and extraordinary general meeting on May 30, 2024, with preparatory documents available for shareholders. The meeting details, including agenda and resolutions, are accessible on the company's website Shareholders Biotechnology Abivax General Meeting Preparatory Documents
PRESS RELEASE published on 05/07/2024 at 22:00, 1 year 10 months ago Abivax assemblée générale ordinaire annuelle et extraordinaire du 30 mai 2024 - Mise à disposition des documents préparatoires Abivax annonce son assemblée générale annuelle et extraordinaire du 30 mai 2024 avec la mise à disposition des documents préparatoires. L'événement se tiendra à Paris Biotechnologie Abivax Assemblée Générale Traitements Thérapeutiques Documents Préparatoires
BRIEF published on 04/30/2024 at 18:05, 1 year 10 months ago ABIVAX rapporte le nombre d'actions et de droits de vote au 31 mars 2024 Autorité Des Marchés Financiers Droits De Vote Capital Social Abivax Informations Réglementaires
BRIEF published on 04/30/2024 at 18:05, 1 year 10 months ago ABIVAX reports the number of shares and voting rights as of March 31, 2024 Share Capital Voting Rights Financial Markets Authority Abivax Regulatory Information
PRESS RELEASE published on 04/30/2024 at 18:00, 1 year 10 months ago ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 31.03.24. ABIVAX communique le nombre d'actions et de droits de vote au 31.03.24, conformément aux dispositions réglementaires. Abivax est une société de biotechnologie axée sur le développement de traitements thérapeutiques Droits De Vote Capital Social Biotechnologie Abivax Traitements Thérapeutiques
Published on 03/23/2026 at 14:05, 5 hours 18 minutes ago Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders
Published on 03/23/2026 at 14:00, 5 hours 23 minutes ago BlackBerry AtHoc Advances Command Center for Faster Response and Tighter Control During Critical Operations
Published on 03/23/2026 at 13:05, 6 hours 18 minutes ago SouthGobi Announces Disclosable and Connected Transaction Deferral of Payment Obligations Under Convertible Debenture and Amended and Restated Cooperation Agreement
Published on 03/23/2026 at 12:32, 6 hours 51 minutes ago Sinopec Announced 2025 Annual Results Annual Payout Ratio Reached 81%
Published on 03/23/2026 at 12:30, 6 hours 53 minutes ago Digi Power X to Announce 2025 Year End Financial Results on March 31st
Published on 03/23/2026 at 19:00, 23 minutes ago PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 16 MARS 2026 au 20 MARS 2026
Published on 03/23/2026 at 18:15, 1 hour 8 minutes ago ISX Financial EU Plc Announces Corporate Name Change to Xryma Plc
Published on 03/23/2026 at 18:09, 1 hour 14 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/23/2026 at 17:54, 1 hour 29 minutes ago EQS-Adhoc: net digital AG publishes 2026 forecast with continued growth in revenue and earnings
Published on 03/23/2026 at 19:08, 15 minutes ago Reporting on share buyback transactions carried out between March 16 and March 20, 2026
Published on 03/23/2026 at 19:08, 15 minutes ago Déclaration de rachats d'actions effectués par la Compagnie de Saint-Gobain entre le 16 et le 20 mars 2026
Published on 03/23/2026 at 18:37, 46 minutes ago ALTAREA : Déclaration d’opérations sur actions propres
Published on 03/23/2026 at 17:45, 1 hour 38 minutes ago ENGIE will build, own and operate its largest onshore wind farm worldwide in Egypt
Published on 03/23/2026 at 17:45, 1 hour 38 minutes ago En Égypte, ENGIE va construire et exploiter son plus grand parc éolien terrestre au monde